Prednisolone plus a disease-modifying antirheumatic drug improved outcomes in early rheumatoid arthritis

May 2006
ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p73
Academic Journal
The article presents information on a study on the effect of prednisolone and modifying antirheumatic drug in early rheumatoid arthritis (RA). It is found that low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug (DMARD) in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. This study included 259 patients between the age group 18 to 80 years. Patients with previous DMARD or glucocorticoid treatment, low bone mineral density, or a history of fragility fracture were excluded from the study.


Related Articles

  • NOD2 allele variants in patients with rheumatoid arthritis. Pawlik, Andrzej; Kurzawski, Mateusz; Gawronska-Szklarz, Barbara; Drozdzik, Marek; Herczynska, Magdalena // Clinical Rheumatology;Jun2007, Vol. 26 Issue 6, p868 

    Recent reports have proven the importance of genetic factors and inflammation in the pathogenesis of rheumatoid arthritis (RA). In the current study, the frequency of NOD2/CARD15 gene variants (R702W, G908R, and L1007fsinsC) was examined in a group of 243 RA patients and 220 healthy controls....

  • Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. Ortega-Hernandez, Oscar-Danilo; Pineda-Tamayo, Ricardo; Pardo, Aryce L.; Rojas-Villarraga, Adriana; Anaya, Juan-Manuel // Clinical Rheumatology;Jul2009, Vol. 28 Issue 7, p767 

    The objective of this study was to examine the clinical and genetic variables associated with extra-articular rheumatoid arthritis (ExRA). This was a cross-sectional study in which 538 Northwestern Colombian patients with rheumatoid arthritis (RA) were included. Information about demographics...

  • Prednisolone plus a disease-modifying antirheumatic drug improved outcomes in early rheumatoid arthritis: COMMENTARY. Schattner, Ami // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p73 

    The article presents the author's views regarding a study on the effect of prednisolone and modifying antirheumatic drug in early rheumatoid arthritis (RA). Prevention of irreversible joint damage, functional decline, and reduced survival is the main goal in the treatment of RA. In the study a...

  • Pipex Adds Late-Stage RA Drug to Pipeline.  // Bioworld Week;8/25/2008, Vol. 16 Issue 34, p4 

    The article reports on the expansion of the autoimmune disease portfolio at specialty pharmaceutical firm, Pipex Phamaceuticals Inc in the U.S. The firm also introduces the addition of an oral heat-stock protein-derived peptide which yields best results for patients undergoing Phase III trial in...

  • Depression als Systemeffekt bei rheumatoider Arthritis. Englbrecht, M.; Wendler, J.; Alten, R. // Zeitschrift für Rheumatologie;Dec2012, Vol. 71 Issue 10, p859 

    The social recognition of depression in general and as a comorbidity in illnesses such as rheumatoid arthritis (RA) has essentially changed in recent years. Previous studies have shown that the occurrence of depression in RA patients is closely related to the individual ways of coping with...

  • Mechanisms of bone loss in rheumatoid arthritis. Findlay, David M.; Haynes, David R. // Modern Rheumatology (Springer Science & Business Media B.V.);Aug2005, Vol. 15 Issue 4, p232 

    Rheumatoid arthritis (RA) is an autoimmune inflammatory disease in which destruction of bone in the joints causes major morbidity. Recent research has shed light on the cell and molecular mechanisms that lead to this osteolysis, all due directly or indirectly to the chronic inflammation. The...

  • S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Kikuta, Junichi; Iwai, Kaori; Saeki, Yukihiko; Ishii, Masaru // Rheumatology International;Jul2011, Vol. 31 Issue 7, p967 

    Therapeutics targeting sphingosine-1-phosphate (S1P), a kind of lipid mediator regulating immune cell trafficking, has been emerging rapidly as a novel line of regimen for autoimmune diseases, including rheumatoid arthritis (RA). Here, we propose that S1P-targeted therapy is beneficial not only...

  • Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Oelzner, Peter; Schwabe, Antje; Lehmann, Gabriele; Eidner, Thorsten; Franke, Sybille; Wolf, Gunter; Hein, Gert // Rheumatology International;Sep2008, Vol. 28 Issue 11, p1143 

    The aim of our study was to compare the significance of risk factors for osteoporosis according to gender and menopausal state in patients with rheumatoid arthritis (RA). Bone mineral density (dual X-ray absorptiometry), cumulative glucocorticoid dose, age, disease duration, body mass index...

  • Synovial membrane enhancement and bone erosion by magnetic resonance imaging for prediction of radiologic progression in patients with early rheumatoid arthritis. Tanaka, Nobuyuki; Sakahashi, Hisashi; Ishii, Seiichi; Sato, Eiichi; Hirose, Kazuya; Ishima, Takumi // Rheumatology International;Mar2005, Vol. 25 Issue 2, p103 

    Objective: The aim of this study was to determine the prognostic factors related to radiographic progression in patients with early rheumatoid arthritis (RA) (less than 1 year after onset) undergoing enhanced MRI at entry. Methods: Demographic characteristics, disease duration, and enhanced MRI...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics